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Introduction 
 
1.1 Spinal Cord Injury 
 
Spinal cord injury (SCI) is devastating event resulting in vast physiological and financial 
loss. In the United States alone, an estimated 300,000 people are living with SCI with 
lifetime financial burden reaching upwards of $4.5 million (NSCISC, 2013). Damage 
from SCI arises in a phasic manner, with the acute mechanical damage leading to a more 
chronic secondary damage mechanism (Oyinbo, 2011). Secondary damage occurs largely 
through an inflammatory cascade mediated by resident and infiltrating immune cells of 
the central nervous system (CNS). While there are a multitude of therapies currently 
being studied for SCI, one promising target is altering the inflammatory phenotype of 
macrophage populations inside of the cord (Gensel, Donnelly, & Popovich, 2011).  
 
1.2 Macrophage Biology 
 
Following spinal cord injury, macrophage/microglia populations activate within a 
spectrum of inflammation ranging between two extreme poles described in vitro (Kigerl 
et al., 2009). On one end are the classically activated (M1) macrophages, which secrete 
an assortment of inflammatory cytokines and release reactive oxidative species (Ding, 
Nathan, & Stuehr, 1988). These cells have proficient antimicrobial activity, while 
exacerbating damage in inflammatory states (Murray & Wynn, 2011). On the other end 
of the spectrum are alternatively activated (M2) macrophages, which are characterized by 
a reparative phenotype consisting of tissue remodeling and neurite growth in the spinal 
cord (Kigerl et al., 2009; Nahrendorf et al., 2007). After SCI, the M1-like phenotype is 
maintained chronically, potentially causing further damage to the injury environment, 
while the M2-like phenotype is down regulated after as little as a week (Kigerl et al., 
2009). Shifting the macrophage inflammatory milieu from a predominantly M1 to a more 
M2 phenotype, therefore, may decrease secondary damage after SCI.  Although this 
dichotomy is an oversimplified description of polarization, describing such macrophage 
populations has aided in explaining the beneficial and damaging effects of macrophages.  
 
 
 
1.3 Microglia 
 
Microglia, the resident immune cell of the CNS, are also major effectors of secondary 
injury after SCI that are thought to follow similar polarization patterns.  In the normally 
functioning CNS, microglia are responsible for maintaining equilibrium through a variety 
of mechanisms. Synaptic remodeling, phagocytosis of debris, and the secretion of 
neurotrophins are only a few of the processes in which microglia ensure proper neuronal 
function in the CNS (Ousman & Kubes, 2012; Popovich & Longbrake, 2008). Upon 
activation by injury or infection, however, microglia release cytotoxic substances and 
inflammatory cytokines which further contribute to neuroinflammation (Czeh, Gressens, 
& Kaindl, 2011). Microglia are involved in many neurodegenerative disorders such as 
Parkinson’s disease, Alzheimer’s disease, and Multiple Sclerosis (Friese & Fugger, 2007; 
More et al., 2013; Solito & Sastre, 2012). In SCI, microglia contribute to acute injury 
through early release of inflammatory cytokines interleukins 1β and 6, and tumor 
necrosis factor-alpha (TNF-α) (Yang et al., 2004). Activation of microglia also results in 
the release of reactive oxygen and nitrogen species which leads to neuronal death 
(Boekhoff et al., 2012; Kaushal et al., 2007). Targeting the detrimental effects of 
microglia while maintaining the synaptic reorganizing and neurotrophic properties is, 
therefore, a potential strategy for reducing inflammatory damage. 
 
1.4 Background on Preconditioning 
 
Preconditioning offers one possible route of utilizing microglial activation to be 
beneficial in neuroinflammatory events. By exposing an inflammatory system to a mild 
noxious stimulus, the system can be primed to be more anti-inflammatory when exposed 
to a subsequent serious stimulus. Possible preconditioning stimuli include ischemia, 
physical trauma, as well as various biochemical additives. This phenomenon has been 
extensively studied in models of stroke, traumatic brain injury (TBI), and myocardial 
protection (Monson et al., 2014; Yamakawa et al., 2014; Yokobori et al., 2013). By 
briefly occluding the carotid artery prior to middle cerebral artery occlusion, investigators 
are able to decrease infarct volume while also decreasing levels of inflammatory cytokine 
IL-1β (Shin et al., 2013). In TBI, cell death and cognitive deficit are decreased in animals 
preconditioned with N-methyl-d-aspartate (NMDA) when compared to controls (Moojen 
et al., 2012).   
 
1.5 Endotoxin Preconditioning 
 
Lipopolysaccharide (LPS) is a component of gram-negative bacterial cell membrane that 
normally elicits inflammatory cascades in immune cells (Beutler & Rietschel, 2003). 
While normally inducing an M1 macrophage activation phenotype (Kigerl et al., 2009), 
LPS also has implications in preconditioning inflammatory systems. In stroke, LPS-
preconditioning decreases the damage done by TNF-α signaling pathways by priming the 
system with initial production of TNF-α (Rosenzweig et al., 2007). It is currently 
believed, therefore, that LPS-preconditioning occurs as a result of regulating cytokine 
signaling through negative feedback mechanisms, as well as through latent expression of 
anti-inflammatory cytokines in response to the initial stimulus (Shpargel et al., 2008). 
Specifically in CNS trauma, LPS-preconditioning has been used as a method of shifting 
the inflammatory phenotype of microglia. After a 4 day injection regimen of LPS prior to 
TBI, microglia express higher levels of M2 genes as well as exhibiting increased synaptic 
“pruning”. This effect resulted in less neuronal cell death and a smaller overall lesion 
volume (Chen et al., 2012).  
 
While preconditioning microglia in the brain has been shown to be beneficial, no such 
work has currently been done in the spinal cord. LPS does not actively cross the blood-
brain barrier (Singh & Jiang, 2004), but instead is thought the signal via 
circumventricular organs (CVOs) to the brain (Rivest, 2003). Under this assumption, 
however, the spinal cord would only exhibit LPS-mediated activation via a trickle down 
from the brain as the spinal cord does not contain CVOs. To examine the potential of 
microglial preconditioning in the spinal cord, we have characterized the spatial 
orientation and activation patterns after peripheral LPS injection. Here, we show that 
systemic LPS activates spinal cord microglia without inducing neuropathology. Our 
results also indicate that LPS may signal directly across spinal cord vasculature to 
microglia, thereby providing an alternative hypothesis to the CVO theory. 
 
 
Materials and Methods 
 
Animals and lipopolysaccharide injection 
Male mice, 8-10 weeks of age, from the C57bl/6 strain were used in these experiments 
(The Jackson laboratories). All experiments were performed in accordance with the 
Institutional Animal Care and Use Committee of The Ohio State University. For four 
days, animals received either 0.1M phosphate buffer saline (PBS) or 1mg/kg LPS (E. 
coli, serotype 055:B5, Sigma) injection intraperitoneally. Prior to each injection, body 
weights were recorded.  
 
Activity Data 
On a subset of animals, open field activity analysis was performed using activity box 
(Animal Activty Meter: Opto M3). Sensors measured vertical and horizontal activity for 
30 min and data were compiled using Accuscan software. Measurements included 
movement time, rest time, vertical activity time, and horizontal movement count. These 
data were analyzed using two-way repeated measures ANOVA on Prism (GraphPad 
Software, Inc; p < 0.05). 
 
Tissue preparation and immunohistochemistry 
 
Twenty-four hours after the final injection, mice were anesthetized with ketamine (27.5 
mg/mL)/xylazine (5 mg/mL) and transcardially perfused with 4% paraformaldehyde/0.1 
M PBS. Spinal cords were removed and fixed for an additional 24 h, then transferred to 
30% sucrose for three days. Tissue was blocked in Tissue-Tek OCT (Sakura) and 
sectioned using a cryostat. Sections were either cut at 10µm or 30µm, depending on the 
staining protocol. For Iba-1 floating sections: 30µm thick sections were floated in 0.1M 
PBS. Sections were then blocked in 4%BSA/0.3%Triton X-100/PBS for 1 h prior to 
primary antibody incubation. Sections were incubated in rabbit anti-Iba-1 (1:1000; Wako; 
Richmond, VA) diluted in blocking reagent overnight at room temperature while agitated 
by orbital shaker. The next day, sections were washed in PBS and then incubated with 
biotinylated goat anti-rabbit secondary antibody (1:1000; Vector Laboratories, 
Burlingame, CA) for 1 h. Sections were then treated with 30% hydrogen peroxide in 
methanol (1:5), stained by avidin-biotin complex (Vector), and developed using 
diaminobenzidine (Vector). Sections were then mounted onto glass slides, dehydrated, 
and coverslipped with Permount (Thermo Fisher Scientific; Waltham, MA). For all 
other stains: 10µm thick sections were mounted onto glass slides and blocked as earlier 
stated. Slides were incubated with primary antibodies overnight. Primary antibodies used 
include: rabbit anti-Iba-1 (1:1000; Wako), rat anti-CD16/32 (1:800; BD Biosciences; San 
Jose, CA), mouse anti-iNOS (1:1000; BD Biosciences), rat anti-CD31 (PECAM-1, 
1:5000; BD Biosciences), mouse anti-NeuN (1:1000; Chemicon, Millipore; Billerica, 
MA). The next day, slides were washed three times in PBS, and then incubated in 
secondary antibodies for 2 h. Secondary antibodies used are: Alexa-488 conjugated goat 
anti-rabbit (1:1000; Life Technologies; Grand Island, NY), Alexa-546 conj. goat anti-rat 
(1:1000; Life Technologies), Alexa-546 conj. goat anti-mouse (1:1000; Life 
Technologies), and Alexa-488 conj. goat anti-mouse (1:1000; Life Technologies). Slides 
were then coverslipped with Immu-mount (Fisher). For cresyl violet staining, slides were 
rinsed in distilled water and then submersed in 0.1% Cresyl Echt Violet (ScyTek 
Laboratories; West Logan, UT) for 20 min. Slides were then rinsed, dehydrated, and 
coverslipped with Permount (Fisher). Histological data were analyzed using Student’s t-
test and two-way ANOVA (gray matter/white matter stain). 
 
Image analysis 
 
Images were captured using a Zeiss Axioplan2 microscope, AxioCam MRm camera, and 
AxioVision imaging software (Carl Zeiss Microscopy; Peabody, MA). All images for a 
given marker were captured using the same exposure settings. Fluorescent images were 
analyzed using MetaMorph (Molecular Devices; Sunnyvale, CA) and all other images 
were analyzed using MCID (Imaging Research; St. Catharine’s, Canada) and ImageJ (US 
NIH; Bethesda, MD). For Iba-1 density, threshold intensities were applied based on Iba-1 
staining (thresholds were consistent throughout all images) and proportional area of Iba-1 
staining was measured. For colocalization expression studies, images were thresholded 
for Iba-1 and the percent area of the second marker was analyzed on Iba-1+ cells. For 
PECAM analysis, images were taken in the ventral horn based on the PECAM channel 
(so as not to be biased by microglia location). Number of microglia in each image were 
counted, and then a proportion of those microglia that associated with PECAM+ vessels 
was calculated. For neuron pathology analysis, images were taken within the ventral horn 
and thresholded based on NeuN intensity. NeuN+ cells were then counted and the total 
area of NeuN was divided by the number of cells in each image to obtain an average 
somal area. Data were analyzed using unpaired, two-tailed t-test in Prism (GraphPad; p < 
0.05).  
 
 
RNA isolation, conversion, and qPCR 
 
Animals used for RNA isolation were perfused using PBS in DEPC water. Spinal cords 
were removed and homogenized in Trizol (Life Techonologies). After isolation, RNA 
concentration purity and concentration were measured via spectrophotometer (NanoDrop, 
ThermoFisher Scientific). 1 µg of RNA was converted to cDNA using M-MLV (Life 
Technologies) reverse transcriptase in a thermal cycler (Eppendorf NA; Hauppauge, NY). 
Quantitative polymerase chain reaction (qPCR) was run on the cDNA through The Ohio 
State University’s Nucleic Acid Share Resource to determine changes in gene expression. 
Readouts were compared to a control curve from pooled cDNA from all samples. Data 
are presented as fold changes compared to the control curve.  
 
Results 
 
LPS injection paradigm induces sickness behavior 
 
To ensure that our LPS was active and triggering the appropriate peripheral immune 
response, we used sickness behavior in the mice as a quantifiable outcome measurement. 
Body weights of all animals were recorded prior to each injection time, as well as just 
before sacrifice. As expected, animals treated with LPS showed a consistent increase in 
percent body mass lost throughout all time points (Fig 1, a). We measured spleen weight 
at time of dissection as another measurement of peripheral immune response. Compared 
to PBS controls, LPS animals had significantly larger spleens, indicating increased 
lymphocyte activity (Fig 1, b). We also measured activity in an open field test to further 
demonstrate sickness behavior. In each parameter measured, LPS treated animals 
displayed increased lethargy and inactivity. As anticipated LPS mice spent significantly 
less time moving (Fig 1, c), rested longer (Fig 1, d), spent less time “rearing” as indicated 
by vertical movement time (Fig 1, e), and had less horizontal movement events (Fig 1, f). 
This data allows us to conclude that our LPS injection paradigm generates the expected 
immune response. 
 
Systemic LPS injection causes widespread microglial activation in the spinal cord 
 
To test our hypothesis that peripherally injected LPS could activate microglia in the 
spinal cord, we used an LPS preconditioning model shown to be beneficial in brain injury 
(Chen et al., 2012). Mice were subjected to daily LPS injections intraperitoneally for four 
days as outlined in the Methods section. To maintain consistency between studies, we 
began with a floating section peroxidase staining method, using Iba-1 to visualize 
microglial activation. At the cervical level, microglia exhibited significantly increased 
proportional area of Iba-1 after LPS injection (Fig 2, a-c). Similar trends in activation 
were seen at both the thoracic (Fig 2, d-f) and lumbar (Fig 2, g-i) levels, with lumbar 
activation reaching statistically significance. High-powered images of microglia show 
differences in cell morphology after LPS treatment. In control animals, microglia 
exhibited the “ramified” morphology normally seen in surveying microglia (Kreutzberg, 
1996) with long, branched processes (Fig 2, a,d,g insets). Conversely, LPS-activated 
microglia retracted their processes and maintained a “bushy” morphology (Fig 2, b,e,h 
insets). These results indicate that repeated doses of LPS, when administered 
peripherally, are able to successfully reach the spinal cord and activate microglia.  
 
 
 
 
 
 
 
 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LPS injection paradigm induces sickness behavior. (a) LPS-treated animals lost body 
weight throughout the injection period. PBS animals gained weight throughout. (b) After 
dissection, spleen weights were measured and normalized to baseline body weight. LPS-
treated animals had significantly larger spleens (***p < 0.001). Activity box 
measurements were taken to observe behavioral differences. (c) LPS treated animals 
moved for significantly less time when compared to PBS controls. (d) LPS animals rested 
for longer periods of time (e) LPS animals vertically “reared” for less time compared to 
controls. (f) LPS animals had less total horizontal movement (* p < 0.05) 
 
 
 
 
Microglial activation is more widespread in gray matter  
 
To assess whether LPS-mediated microglial activation is region specific in the spinal 
cord, we analyzed the extent of activation in the gray matter versus the white matter. As 
with previous data, total microglia activation increased in LPS-treated animals at all 
levels, although only reaching significance in the cervical cord (Fig 3, g). When gray and 
white matter activation is parsed apart, however, it is evident that microglia activation 
occurs more extensively in the gray matter. Quantification of Iba-1 proportional area in 
PBS treated animals showed no significant differences in activation between gray matter 
and white matter at baseline (Fig 3, h,j,l). This indicates, therefore, that the differences 
seen in LPS treated animals are due to a change in the amount of microglial activation 
and not simply differences in the amount of microglia originally present in those areas. 
Differences in microglia subpopulations within the spinal cord activate in functionally 
distinct ways as shown in a model of spinal cord injury (McKay, 2007). We hypothesize, 
therefore, that the differences in activated microglia density from endotoxin exposure are 
due to these distinct populations.  Generally, there was noticeably more activation in the 
ventral horns of the spinal cord compared to other areas of gray matter. While these 
specific differences were not quantified, it provided us a target area for further analysis 
on microglial function. 
 
 
Extent of microglial activation is not altered by varying staining protocols 
 
In order to test the functional implications of microglial activation later on, we first 
wanted to verify that we would observe similar activation patterns when using 
fluorescently stained sections that were pre-mounted on slides. Similar to the floating 
section peroxidase method, microglia fluorescently labeled with Iba-1 exhibited 
significant activation after LPS. Interestingly, thoracic microglia were significantly 
activated in slide-mounted sections (Fig 4, f) while failing to reach significance in the 
floating sections (Fig 2, f). Also, microglial activation of LPS-treated sections at the 
lumbar level reached nearly three times that of controls (Fig 4, g-i). This data provides 
evidence that fluorescently stained slide-mounted sections are more sensitive to LPS-
induced changes in microglial reactivity, allowing us to further explore immunostaining 
using this method. 
 
Primed microglia interact uniquely with spinal cord anatomy 
 
To further characterize the implications of LPS-primed microglia in the spinal cord, we 
sought to observe how these cells were spatially associating with various components of 
the spinal cord, specifically within the gray matter. Similar to activation patterns seen in 
the ventral horn, microglia in the dorsal horn exhibited increased activation in animals  
 
 
 
 
 
Figure 2 
 
 
 
 
 
 
Microglia morphology indicates increased activation in the ventral horns of LPS 
treated animals when compared to PBS controls. (a,d,g) PBS treated animals exhibit 
microglia with long processes and round body (see insets). (b,e,h) LPS-treated microglia 
have a more robust and amorphous morphology. (c,f,i) Quantification of proportional 
area of Iba-1 in the ventral horn indicates significant differences between group in the 
cervical and lumbar spinal cord. Images taken at 10x. Scale bar = 200um. Insets taken at 
40X. Scale bar = 20um. *p<0.05 **p<0.01 
 
 
treated with LPS (Fig 5, a,d). As expected, dorsal horn microglia were more “bushy” in 
appearance with drawn in processes. The central canal of the spinal cord was lined with 
proliferative cells called ependyma which, when activated, can rescue neurological 
function in the diseased and injured cord (Johansson et al., 1999; Moreno-Manzano et al., 
2009). We wanted to see if primed microglia interacted with the central canal differently 
compared to saline treated cells. In general, LPS-treated microglia surrounded the central 
canal in a more robust fashion, interacting extensively with the presumed ependyma. 
Control microglia, while located around the central canal, sent only a few processes in to 
survey the ependymal cell layer (Fig 5, b,e).  
 
 
Differences in microglial involvement with spinal cord blood vessels were also seen. 
Blood vessel lumen were largely surrounded by LPS-activated microglia, while control 
microglia were not associated with vessels as frequently (Fig 5, c,f). In all of the sections 
analyzed, nearly every noticeable vessel in LPS-treated animals includeed a microglia 
surrounding it. This phenomenon suggests a possible route of signaling for the LPS. 
There is evidence, however, that LPS does not cross the blood-brain barrier directly, and 
may instead signal via receptors on endothelium (Banks & Robinson, 2010). The 
numerous associations of microglia with vasculature seen with routine histology provide 
evidence that the activation of microglia is through LPS signaling across blood vessels. 
 
Together, these data suggest that LPS-primed microglia have unique interactions within 
the gray matter of the spinal cord, while also providing a hypothesis to how LPS is 
signaling to spinal cord microglia. 
 
Primed microglia exhibit increased association with blood vessels in the spinal cord 
 
In order to further explore the hypothesis that LPS is activating microglia through 
signaling across spinal cord vasculature, we stained specifically for platelet endothelial 
cell adhesion molecule-1 (PECAM-1). This allowed us to visualize blood vessels that 
were traversing in multiple different planes as opposed to cross-sectional lumen seen in 
figure #. We could also document colocalization of Iba-1 and PECAM-1, allowing us to 
further examine how microglia are interacting with vasculature. There was a striking 
difference in the amount of microglia involvement with vasculature after LPS injection 
when compared to saline controls. PBS treated animals exhibited only slight interactions 
with blood vessels at all levels of the spinal cord (Fig 6, a,d,g). When interactions did 
exist, they are usually due to microglia extending out processes to survey the vessels. 
Conversely, LPS treated microglia were often found in close contact with vessels, 
interacting by wrapping themselves around the vasculature (Fig 6, b,e,h). Instead of 
merely reaching out processes, LPS-treated microglia encompassed the vessel using the 
entire cell body and collection of processes. Interestingly, in LPS treated animals, 
microglia that are associated with vessels seemed to be more robustly activated 
morphologically than those that were not interacting with vessels. This could indicate 
further necessity of trans-endothelial signaling to activate spinal cord microglia. 
Quantification of the proportion of microglia associated with vessels shows statistical 
significance at all levels of the spinal cord. (Fig 6, c,f,i). Because there is widespread  
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
LPS activates microglia differently depending on location in the spinal cord. LPS 
treated animals (b,d,f) exhibited higher microglial activation at all levels compared to 
PBS (a,c,e) controls. (g,i,k) Quantification of proportional area of Iba-1 staining for the 
entire spinal cord section showed significant differences at the cervical level (g) but not at 
thoracic or lumbar (i,k). Within the cervical level, microglia occupied more than 2x the 
surface area in gray matter compared with white matter (h). No such spatial differences 
were seen in thoracic and lumbar quantification (j,l) Images taken at 2.5x. 
*p<0.05,**p<0.01,***p<0.001 
 
 
 
Figure 4 
 
 
 
 
 
 
 
 
Slide mounted, fluorescently stained Iba-1+ microglia exhibit similar activation 
patterns as floating section stain. Microglia display similar morphological differences 
as seen in peroxidase staining. This activation is seen at cervical (a,b), thoracic (d,e), and 
lumbar (g,h) levels. (c,f,i) Quantification of Iba-1 % area shows significant differences 
between groups at all levels. (i) The lumbar cord has the highest differences between 
groups with the LPS group demonstrating 3x the amount of microglial activation. Images 
taken at 20x. Scale bar, 20µm. 
 
 
 
 
 
 
 
activation throughout the spinal cord as well as similar patterns of vasculature 
association, it seems that LPS is not reaching the spinal cord via trickling down from the 
brainstem CVOs. This data indicates, instead, that LPS is likely signaling across 
vasculature endothelium. 
 
Activated microglia do not induce noticeable neuropathology  
 
In order to determine whether or not preconditioned microglia cause neuronal death or 
pathology in the spinal cord, we first looked to routine histology. Using cresyl violet 
staining, we were able to visualize neuron morphology as well as changes in 
extraneuronal cells. While pathological neurons often exhibit an “eccentric nucleolus” 
which is indicative of chromatolysis (Rees, 1971), neurons treated with LPS showed 
normal neuronal morphology (Fig 7, a,d). This analysis was performed within the 
cervical ventral horn because morphological differences would be more evident in these 
large cells. When we looked at the association of extraneuronal cells around neurons, we 
noticed some slight differences. In control animals, when we noticed cells surrounding 
neurons, there was usually only one cell associated with the neuron (Fig 7, b). In LPS 
treated cells, however, there were usually two to three cells per neuron (Fig 7, e). 
Although we are not certain of the identity of these cells based on this analysis, we 
presume that these cells are likely microglia interacting with neurons uniquely between 
groups.  
 
To determine if this LPS preconditioning paradigm affects morphology of other cells 
within the spinal cord, we examined ependymal cells surrounding the central canal. 
Ependymal cells are neural stem cells capable of proliferating into a wide variety of cell 
types including neurons and astrocytes (Johansson et al., 1999). In our model, we saw 
markedly different morphologies in ependyma. In saline treated animals, ependyma lined 
the central canal in a single cell layer with the cells achieving a columnar shape (Fig 7, 
c). LPS-treated ependymal cells, however, looked to be more rounded in shape and occur 
often in multiple cell layers (Fig 7, f). This phenomenon can be explained by activation 
and proliferation of ependyma. Should this be the case, this injection model may also 
serve as a tool for inducing proliferation in ependyma. 
 
In order to further explore possible neuropathology, we analyzed the amount and size of 
neurons in the ventral horn using NeuN staining. We saw similar morphology of neurons 
in both control and LPS-treated spinal cords (Fig 8, a-b). To compare the number of 
neurons in the ventral horn, we counted NeuN+ cells in multiple 1500µm2 sample areas 
and found that the average number of cells within this area were not different between 
groups (Fig 8, c). Similarly, the average somal areas of these cells were not appreciably  
different between groups (Fig 8, d). These data suggest that microglial activation via LPS 
preconditioning does not induce neuropathology. 
 
 
 
Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activated microglia exhibit unique associations with spinal cord gray matter.  
(a,d) Microglial activation at the dorsal horn shares similar patterns with the ventral horn. 
LPS microglia, again, have a more amorphous, bushy morphology. Images at 10x. Scale 
bar, 200µm (b,e) Generally, more microglia are associated around ependymal cells of the 
central canal after LPS treatment. (c,f) LPS treated microglia are found associated with 
vessels in large numbers (#) compared to PBS controls where many vessels do not have 
any interactions with microglia (*) Images (b,c,e,f) taken at 40x. Scale bar, 60µm.  
 
Figure 6 
 
 
 
 
 
 
 
 
 
 
LPS-activated microglia associate extensively with spinal cord vasculature. Staining 
for platelet endothelial cell adhesion molecule-1 (PECAM-1, vessels) and Iba-1 
(microglia) shows changes in microglia association with vessels. PBS-treated microglia 
(a,d,g) show very little association with vasculature as indicated by arrow heads. LPS 
cells, however, (b,e,h) wrap around PECAM-1+ vessels (arrows). Quantification (c,f,i) 
demonstrates that LPS animals have higher proportion of microglia which associate with 
vessels. This trend is significant at all levels of the spinal cord. Images taken at 40x. 
Scale bar, 10µm. **p < 0.01, *** p < 0.001 
 
LPS preconditioning induces an inflammatory expression profile in the spinal cord  
 
In order to determine the functional capabilities of preconditioned microglia, we  
examined a wide array of known pro- and anti-inflammatory surface markers. Based on 
previous work, we expected primed microglia to express anti-inflammatory markers. 
Instead, however, neither LPS nor PBS showed any discernible expression of anti-
inflammatory markers Arginase-1 and CD206 (Data not shown). Antibodies against these 
markers were shown to be effective using test tissue known to positively express the 
markers. Differences in inflammatory markers were seen between groups, however. 
CD16/32 are a part of the Fc gamma receptor family, which are involved in acute and 
chronic inflammation (van Lent et al., 2001). In LPS treated microglia, there were 
significant increases in CD16/32 expression (Fig 9). Inducible nitric oxide synthase 
(iNOS) is an enzyme that is induced by LPS (Chan & Riches, 2001). Here, microglia 
exposed to repeated doses of LPS expressed higher levels of iNOS than PBS controls as 
demonstrated by immunohistochemical analysis (Fig 10). While these results were not 
significant, the quantification exhibits a noticeable trend (Fig 10, g). These data indicate a 
inflammatory phenotype for preconditioned microglia based on expression patterns. 
 
In order to determine if genetic expression in the spinal cord follows the inflammatory 
patterns seen specifically in microglia protein expression, we performed qPCR on spinal 
cord homogenate. We targeted mainly inflammatory genes due to trends discussed 
earlier. Expression of major inflammatory mediator, IL-1β,  was increased in LPS treated 
animals (Fig 11, a). Interestingly, we saw no increase in expression of other inflammatory 
genes we targeted (Fig 11, b-c). This suggests a specific inflammatory mechanism, 
possibly mediated by IL-1β. As expected, we saw no changes in expression of Arg1, a 
major marker of anti-inflammatory response (Fig 11, d). 
 
 
Discussion 
 
In the present study, we have elucidated a novel tool in studying microglial effects in 
spinal cord inflammation. Basing our model off of endotoxin preconditioning, we are 
able to activate centrally located microglia through peripheral administration of LPS. 
These cells exhibit distinct morphological changes after exposure to LPS while 
demonstrating unique interactions with gray matter landmarks. Through the use of 
routine histology and specific markers for vasculature, we now hypothesize that LPS 
signals across endothelium of blood vessels as a mechanism of activating spinal cord 
microglia. Although robustly activated, these microglia are not inducing noticeable 
neuropathology as demonstrated through neuron size, morphology, and quantity. 
Ependymal cells, however, display an altered morphology that may be a possible 
indicator of activation. While morphologically active, we also found that LPS-primed 
microglia are functionally activated, expressing increased surface inflammatory markers 
and mRNA. These data suggest that microglia are capable of being activated via 
peripheral mechanisms without damaging the spinal cord.  
 
Preconditioning inflammatory systems to decrease damage 
 
The concept of preconditioning has been extensively studied in various models of 
inflammation. The administration of a normally detrimental stimulus can induce 
protection to subsequent stimuli through a multitude of various mechanisms. In the heart, 
ischemic preconditioning can lead to myocardial protection through various mechanisms 
including circulating factors, anti-inflammatory transcription changes, and neural 
responses (Hausenloy & Yellon, 2008). Ischemic preconditioning also has clinical 
implications in both cardiac surgery and patients who have experienced hemorrhage of 
the brain (Ali et al., 2007; Hausenloy et al., 2007; Koch et al., 2011). The therapeutic 
potential of ischemic preconditioning is vast, however the cellular and molecular 
mediators of this mechanism are poorly understood. 
 
Similarly, endotoxin preconditioning (through LPS administration) has shown great 
potential in neuroprotection. After a low dose of LPS, rodent brains are protected against 
a subsequent larger dose of LPS, cerebral ischemia, and traumatic brain injury (Kumral et 
al., 2012; Tasaki et al., 1997; Longhi et al., 2011).  The mechanism of this 
counterintuitive phenomenon is thought to be through Toll-like receptor (TLR-) 4 
induction of inflammatory genes. Vartanian et al. (2011) showed that mice 
preconditioned with LPS prior to middle cerebral artery occlusion (MCAO) exhibited a 
shift to Myd88-independent Toll/IL-1R domain-containing adaptor inducing IFN (TRIF) 
signaling which leads to increased expression of anti-inflammatory genes. Furthermore, 
there is evidence that inflammatory cytokine tumor necrosis factor (TNF-) alpha may be 
necessary in inducing neuroprotective preconditioning (Rosenzweig et al., 2007). Basal 
levels of inflammatory marker expression, therefore, seem to be critical in 
preconditioning. Currently, endotoxin preconditioning for neuroinflammation is studied 
almost exclusively in the brain. There is a draught in the literature regarding 
preconditioning in the spinal cord, especially that involving LPS, save a few studies done 
in rat SCI (Li et al., 2013). This study, however, has characterized a tool of studying 
preconditioning in the spinal cord through the manipulation of microglia. 
 
 
Microglia as targets of neuroprotection through preconditioning 
 
Because of the implications of LPS receptor TLR-4 in preconditioning, a logical cellular 
target for preconditioning in the CNS are microglia. Microglia are capable of a wide 
range of functions depending on their activation pattern, making them especially 
interesting and complicated targets for preconditioning. The responses of microglia to 
endotoxin preconditioning vary greatly depending on the injection protocol. With lower 
doses (0.2 mg/kg) or single injections, microglia do not exhibit the robust activation 
patterns that we observed (Chen et al., 2012; Rosenzweig et al., 2004). This study and 
similar ones performed in the brain suggest that microglial activation occurs due to 
repeated exposure to LPS.  Despite early opinions of microglia being solely detrimental 
cells in models of CNS injury or disease, studies now show the neuroprotective potential 
of microglia. Cultured microglia, when stimulated with nerve fragments to simulate CNS  
 
Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cresyl violet staining demonstrates cellular changes in the spinal cord.  
(a,d) Demonstrations of “normal” neurons. Neurons have centralized nucleoli and regular 
shape. (b,e) Neurons in contact with extraneuronal cells, presumably microglia. PBS 
treated animals exhibit neurons in contact with only 1 cell (arrowheads) while LPS 
treated animals typically have 2-3 associated cells (arrows) (c,f) Ependymal cells around 
the central canal in LPS treated animals are more rounded and numerous, forming 
multiple layers around the central canal. (a,c,d,f) Taken at 40x. Scale bar, 60µm. (b,e) 
Taken at 20x. Scale bar, 100µm 
Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preconditioned microglia do not exhibit neuropathology. Neurons stained with NeuN 
were analyzed for number and size. (a,b) Representative images of ventral horn neurons. 
(c) There are no discernible differences in neuron number in the ventral horn between 
groups. (d) Neurons in both groups had similar neuron size with no noticeable differences 
in shape throughout the gray matter. Images at 40x. Scale bar, 10µm. 
 
 
 
 
injury, secrete neurotrophic factors that are beneficial to neuron growth and survival 
(Glanzer et al., 2007). Studies in vivo have also shown neurogenic and neurotrophic 
properties of microglia in the context of stroke and excitotoxicity (Liang et al., 2010; 
Thored et al., 2009).  
 
While these reparative functions are the long-term goal in endotoxin preconditioning, we 
also needed to characterize possible detrimental effects known to be associated with 
activated microglia. Interestingly, many of the damaging inflammatory functions of 
microglia can be a result of TLR4 signaling, the same receptor implicated in 
neuroprotective endotoxin preconditioning (Lehnardt, 2010). Our histological analysis 
(Fig 7,8) suggests that the LPS injection paradigm used in this study does not induce 
neuropathology normally seen with LPS stimulated microglia (Chao, 1992). This 
phenomenon may be due to a variety of factors. Due to the repeated nature of the 
injection protocol, neuronal pathology may be occurring previous to the date of 
perfusion. Should this be the case, however, we would expect to see an overall decrease 
in neurons within the gray matter, which is not the case (Fig 8, c). We may also be seeing 
a shift in TLR4 signaling cascades as discussed previously. This occurrence should be 
accompanied by an increase in anti-inflammatory genes via IRF3 signaling. Our genetic 
analyses, although on total spinal cord homogenate, demonstrated an increase in IL-1β, a 
prominent inflammatory factor. The specific mechanism of preconditioning in this model, 
therefore, needs to be uncovered.  
 
Vasculature endothelium as a possible signaling intermediate for LPS-preconditioning 
 
In a similar model of microglia preconditioning in the brain, investigators discovered that 
non-hematogenous TLR4 signaling is necessary for LPS-preconditioning (Chen et al., 
2012).  This suggests that microglial and/or endothelial TLR4 signaling is responsible for 
the LPS signaling across the blood-brain barrier. Our findings of microglial interactions 
with blood vessels further strengthen this hypothesis. We now believe that circulating 
LPS is docking to TLR4 receptors on the endothelium on spinal cord vasculature is 
responsible for signaling into the centrally located microglia. This interaction may be 
through cytokine secretion by activated endothelium (Dauphinee & Karsan, 2006), which 
attracts microglia to the vessels, leading to activation. This hypothesis, however, will 
require further investigation.  
 
Inflammatory characterization of endotoxin conditioned microglia 
 
We also saw an increase in inflammatory markers and gene expression after 
preconditioning. In contrast to Chen et al. (2012), who showed that microglia in their 
model expressed increased anti-inflammatory genes after brain injury, we seem to have 
induced a inflammatory polarized microglial population. Despite following the injection 
protocol described in their study, we see appreciable differences in microglia phenotype. 
This difference in inflammatory phenotype may be due to when the preconditioned 
microglia are analyzed. Prior to the major stimulus against which we are attempting to 
protect, microglia may exhibit a more inflammatory expression pattern. Once exposed to  
 
Figure 9 
 
 
 
 
 
 
 
 
Immunostaining for CD16/32 is increased in cells treated with LPS. (a-c) PBS 
animals exhibit cells positive for microglial marker Iba-1 (green, arrowheads), but not 
also positive for CD16/32 (red). (d-f) LPS treated animals exhibit cells dually positive for 
Iba-1 and CD16/32 (arrows), indicating microglia expressing CD16/32. (g) 
Quantification of the % area of Iba-1+ cells also positive for CD16/32 indicates 
significant differences between groups. Images taken at 20x with insets at 40x. 20x scale 
bar, 20um. 40x scale bar, 5µm. *p<0.005 
 
 
Figure 10 
 
 
 
 
 
 
LPS activation causes microglia to increase expression of iNOS (a-c) PBS treated 
animals did not have noticeable amounts of iNOS expressed in Iba-1+ cells. There were, 
however, cells resembling neurons that expressed the marker (*). Microglia that do not 
have expression of iNOS are denoted by arrowheads. (d-f) LPS treated animals have 
increased numbers of microglia expressing iNOS (arrows) as seen through 
immunostaining. (g) Although not reaching significant levels, there is a trend of increased 
iNOS expression in Iba-1+ cells in LPS treated animals. Images taken at 20X with insets 
at 40X. 20x scale bar, 20µm. 40x scale bar, 5µm. 
 
 
 
 
 
 
a large inflammatory stimulus such as injury, however, microglia may shift to an anti-
inflammatory state. Because brain and spinal cord inflammatory physiology differ 
(Schnell et al., 1999), the microglial response to LPS-preconditioning may very well be 
different as well. 
 
A particularly interesting finding of this study is the increase in IL-1β gene expression 
without increases in other inflammatory genes. Studies in the brain have shown that LPS 
induced activation of the CNS may be due to IL-1β acting on endothelial cells (Quan, He, 
& Lai, 2003). Because the increase in IL-1β expression is measured from spinal cord 
homogenate, it cannot be determined specifically which cells are increasing the 
expression. Also, it should be noted that mRNA expression does not directly correlate 
with physiological production of IL-1β. Α study in vitro shows that endothelial cells, 
when activated by LPS, express IL-1β (Wang et al., 2011). The same study also showed 
that endothelial cells do not exhibit endotoxin tolerance, whereas glial cells do (as 
indicated by downregulated cytokine expression). These endothelial cells also exhibit 
increased expression of MyD88 and TRIF, which offers a possible mechanism of 
endothelial involvement in LPS preconditioning. As mentioned earlier, TRIF signaling 
has been implicated in the benefits of LPS preconditioning. One possible mechanism of 
preconditioning in this model, therefore, is that circulating LPS activates endothelial cells 
causing them to express IL-1β. This IL-1 expression leads to activation of TRIF 
pathways within the endothelium, leading to further endothelial activation or eventual 
expression of anti-inflammatory genes. The details of how LPS, IL-1β, and endothelium 
interact to precondition microglia are not fully understood, but this study sheds light on 
how these might interact to activate, and eventually precondition, microglia within the 
spinal cord. 
 
While the increase in inflammatory surface markers in our model of LPS-preconditioning 
may seem detrimental to future inflammatory stimuli, low-levels of inflammation have 
been shown to have beneficial properties. TNF-α is implicated with remyelination and 
neuroprotection (Arnett et al., 2001; Turrin & Rivest, 2006), while IL-1β aids in the 
production of nerve growth factor CNTF (Herx, Rivest, & Yong, 2000). Because we saw 
no noticeable damage to nervous tissue, we believe that preconditioned microglia are not 
expressing dangerous levels of inflammatory signals due to LPS administration. In order 
to verify this hypothesis, however, ex vivo co-cultures of treated microglia with neurons 
may be beneficial.  
 
Concluding remarks and significance 
 
Within the central nervous system, a crucial homeostasis must be kept in both naïve and 
damaged states. After a major insult to the CNS, neuroinflammation can cause an acute 
occurrence to shift to a more chronic condition, exacerbating damage to nervous tissue. 
There is a need, therefore, to identify cellular and molecular targets of intervention. Due 
to their early involvement in major inflammatory events in the CNS and their 
documented beneficial properties, microglia have the potential to act as cellular targets. 
Here, we have characterized a model of preconditioning in the spinal cord that is capable 
of activating microglia without invasive injection protocols. We hypothesize that these 
morphologically and functionally active cells will be neuroprotective when exposed to a 
more severe inflammatory stimulus based on literature referenced above. This study, 
therefore, will act as a useful tool in translating endotoxin preconditioning into many 
models of spinal cord disease and injury. This will lead to a more expansive knowledge 
on how microglia affect the compromised spinal cord, and how they can be manipulated 
to be advantageous in pathological states. 
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